Tolvaptan
Tolvaptan structure
|
Common Name | Tolvaptan | ||
|---|---|---|---|---|
| CAS Number | 150683-30-0 | Molecular Weight | 448.941 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 594.4±50.0 °C at 760 mmHg | |
| Molecular Formula | C26H25ClN2O3 | Melting Point | 219-222°C | |
| MSDS | Chinese USA | Flash Point | 313.3±30.1 °C | |
|
Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial).
Am. J. Cardiol. 114(11) , 1713-21, (2014) We investigated the clinical profiles associated with serum uric acid (sUA) levels in a large cohort of patients hospitalized for worsening chronic heart failure with ejection fraction (EF) ≤40%, with specific focus on gender, race, and renal function based i... |
|
|
Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model.
J. Am. Soc. Nephrol. 26(1) , 39-47, (2015) Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of ESRD. A central defect associated with ADPKD pathology is elevated levels of 3', 5'-cyclic AMP (cAMP). Compounds such as tolvaptan and pasireotide, which indirectly reduce adenylyl cyc... |
|
|
Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
Circ. Heart Fail. 6(1) , 47-52, (2013) Arginine vasopressin (AVP) levels are elevated in proportion to heart failure severity and are associated with higher cardiovascular mortality in ambulatory patients. However, the relationship between baseline and trends in AVP with outcomes in patients hospi... |
|
|
Tolvaptan for the treatment of hyponatremia and hypervolemia in patients with congestive heart failure.
Future Cardiol. 9(2) , 163-76, (2013) Patients with heart failure often show increased arginine vasopressin secretion and enhanced sympathetic and renin-angiotensin-aldosterone activation, which accelerate renal water reabsorption, causing water retention and volume overload. Tolvaptan is an oral... |
|
|
Tolvaptan for heart failure patients with volume overload.
Cardiovasc. Drugs Ther. 25 Suppl 1 , S1-4, (2011)
|
|
|
Tolvaptan: a new therapeutic agent.
Rev. Recent Clin. Trials 6(2) , 177-88, (2011) Tolvaptan is a new agent in the treatment of normovolemic and hypervolemic hyponatremia. It is a V(2) receptor antagonist inducing free water diuresis. It has been recently approved in USA and Europe for the treatment of hyponatremia associated with SIADH, ci... |
|
|
Role of tolvaptan in acute decompensated heart failure.
Expert Rev. Cardiovasc. Ther. 6(5) , 601-8, (2008) Acute decompensated heart failure accounts for more than 1 million hospitalizations in the USA every year. Currently, the most common treatment for symptom relief is the use of loop diuretics, despite recent concerns for potential adverse effects. With the gr... |
|
|
Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease.
Ann. Intern. Med. 159(6) , 382-9, (2013) Chinese translationIn the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) trial, tolvaptan significantly reduced expansion of kidney volume and loss of kidney function.To determine how the b... |
|
|
The disconnect between phase II and phase III trials of drugs for heart failure.
Nat. Rev. Cardiol. 10(2) , 85-97, (2013) Hospitalization for heart failure (HF) is a clinical entity associated with high postdischarge morbidity and mortality, yet few therapies are available to improve outcomes in patients with this condition. In the past decade, large phase III studies of HF trea... |
|
|
Correction of hyponatremia by tolvaptan before left ventricular assist device implantation.
Int. Heart J. 53(6) , 391-3, (2012) Hypervolemic hyponatremia is often complicated with advanced heart failure together with increased excretion of sodium by diuretics. Tolvaptan, an oral vasopressin-2-receptor antagonist, has been previously reported to improve congestion and correct hyponatre... |